IL109871A - A process for turning Loracraff Dihydrate into Loracerb Monohydrate - Google Patents
A process for turning Loracraff Dihydrate into Loracerb MonohydrateInfo
- Publication number
- IL109871A IL109871A IL10987194A IL10987194A IL109871A IL 109871 A IL109871 A IL 109871A IL 10987194 A IL10987194 A IL 10987194A IL 10987194 A IL10987194 A IL 10987194A IL 109871 A IL109871 A IL 109871A
- Authority
- IL
- Israel
- Prior art keywords
- monohydrate
- dihydrate
- loracarbef
- crystalline
- temperature
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D463/00—Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D463/10—Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
- C07D463/14—Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hetero atoms directly attached in position 7
- C07D463/16—Nitrogen atoms
- C07D463/18—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof
- C07D463/20—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D463/22—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen further substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/071,550 US5374719A (en) | 1993-06-04 | 1993-06-04 | Process for converting loracarbef dihydrate to loracarbef monohydrate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL109871A0 IL109871A0 (en) | 1994-10-07 |
| IL109871A true IL109871A (en) | 1998-08-16 |
Family
ID=22102051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL10987194A IL109871A (en) | 1993-06-04 | 1994-06-02 | A process for turning Loracraff Dihydrate into Loracerb Monohydrate |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US5374719A (pt) |
| EP (1) | EP0627430B1 (pt) |
| JP (1) | JP3442479B2 (pt) |
| KR (1) | KR100311699B1 (pt) |
| CN (1) | CN1042424C (pt) |
| AT (1) | ATE146472T1 (pt) |
| AU (1) | AU678000B2 (pt) |
| BR (1) | BR9402149A (pt) |
| CA (1) | CA2125001C (pt) |
| CO (1) | CO4230100A1 (pt) |
| CZ (1) | CZ283468B6 (pt) |
| DE (1) | DE69401163T2 (pt) |
| DK (1) | DK0627430T3 (pt) |
| ES (1) | ES2097002T3 (pt) |
| FI (1) | FI108132B (pt) |
| GR (1) | GR3022111T3 (pt) |
| HU (1) | HU217066B (pt) |
| IL (1) | IL109871A (pt) |
| MY (1) | MY110724A (pt) |
| NO (1) | NO306302B1 (pt) |
| NZ (1) | NZ260653A (pt) |
| PE (1) | PE13195A1 (pt) |
| PH (1) | PH30304A (pt) |
| PL (1) | PL174539B1 (pt) |
| RU (1) | RU2124013C1 (pt) |
| TW (1) | TW252980B (pt) |
| UA (1) | UA27812C2 (pt) |
| YU (1) | YU33394A (pt) |
| ZA (1) | ZA943827B (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5550231A (en) * | 1993-06-15 | 1996-08-27 | Eli Lilly And Company | Loracarbef hydrochloride C1-C3 alcohol solvates and uses thereof |
| US5580977A (en) * | 1995-03-01 | 1996-12-03 | Eli Lilly And Company | Process for preparing loracarbef monohydrate |
| US20070225285A1 (en) * | 2005-11-04 | 2007-09-27 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3531481A (en) * | 1969-04-21 | 1970-09-29 | Lilly Co Eli | Method for manufacture of crystalline cephalosporin |
| US3502663A (en) * | 1969-04-21 | 1970-03-24 | Lilly Co Eli | Crystalline cephalosporin,method for its manufacture |
| EG18529A (en) * | 1987-10-06 | 1993-04-30 | Lilly Co Eli | Process for preparing b-lactam hydrate |
| CA2002596A1 (en) * | 1988-11-14 | 1990-05-14 | Thomas M. Eckrich | Hydrates of b-lactam antibiotic |
| US4977257A (en) * | 1988-11-14 | 1990-12-11 | Eli Lilly And Company | DMF solvates of a β-lactam antibiotic |
-
1993
- 1993-06-04 US US08/071,550 patent/US5374719A/en not_active Expired - Lifetime
-
1994
- 1994-06-01 TW TW083105006A patent/TW252980B/zh active
- 1994-06-01 CZ CZ941342A patent/CZ283468B6/cs not_active IP Right Cessation
- 1994-06-01 PE PE1994243644A patent/PE13195A1/es not_active Application Discontinuation
- 1994-06-01 AT AT94303945T patent/ATE146472T1/de not_active IP Right Cessation
- 1994-06-01 DK DK94303945.3T patent/DK0627430T3/da active
- 1994-06-01 PL PL94303676A patent/PL174539B1/pl not_active IP Right Cessation
- 1994-06-01 NZ NZ260653A patent/NZ260653A/en unknown
- 1994-06-01 ZA ZA943827A patent/ZA943827B/xx unknown
- 1994-06-01 BR BR9402149A patent/BR9402149A/pt not_active Application Discontinuation
- 1994-06-01 DE DE69401163T patent/DE69401163T2/de not_active Expired - Fee Related
- 1994-06-01 ES ES94303945T patent/ES2097002T3/es not_active Expired - Lifetime
- 1994-06-01 EP EP94303945A patent/EP0627430B1/en not_active Expired - Lifetime
- 1994-06-02 NO NO942048A patent/NO306302B1/no not_active IP Right Cessation
- 1994-06-02 UA UA94005241A patent/UA27812C2/uk unknown
- 1994-06-02 MY MYPI94001408A patent/MY110724A/en unknown
- 1994-06-02 CA CA002125001A patent/CA2125001C/en not_active Expired - Fee Related
- 1994-06-02 CO CO94023737A patent/CO4230100A1/es unknown
- 1994-06-02 AU AU64516/94A patent/AU678000B2/en not_active Ceased
- 1994-06-02 KR KR1019940012340A patent/KR100311699B1/ko not_active IP Right Cessation
- 1994-06-02 IL IL10987194A patent/IL109871A/en not_active IP Right Cessation
- 1994-06-02 PH PH48386A patent/PH30304A/en unknown
- 1994-06-03 RU RU94019424A patent/RU2124013C1/ru not_active IP Right Cessation
- 1994-06-03 CN CN94106984A patent/CN1042424C/zh not_active Expired - Fee Related
- 1994-06-03 FI FI942633A patent/FI108132B/fi not_active IP Right Cessation
- 1994-06-03 HU HU9401675A patent/HU217066B/hu not_active IP Right Cessation
- 1994-06-03 JP JP12228394A patent/JP3442479B2/ja not_active Expired - Fee Related
- 1994-06-03 YU YU33394A patent/YU33394A/sh unknown
-
1996
- 1996-12-19 GR GR960403422T patent/GR3022111T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0897386B1 (en) | Process for the preparation of a magnesium salt of a substituted sulphinyl heterocycle | |
| SK134399A3 (en) | Cefdinir in the form of a salt with dicyclohexylamine, a process for its production and its use | |
| EA002386B1 (ru) | Полиморфная форма гидросульфата клопидогрела | |
| UA72777C2 (en) | A process for the preparation of amorphous atorvastatin calcium | |
| GB2336364A (en) | Paroxetine methanesulfonate | |
| US6020487A (en) | Intermediates and process for preparing olanzapine | |
| EP0627430B1 (en) | Process for converting loracarbef dihydrate to loracarbef monohydrate | |
| AU2001265377B2 (en) | Crystal modification of fexofenadine | |
| US20020086993A1 (en) | Crystal modification | |
| US5399686A (en) | Loracarbef isopropanolate and a process for converting loracarbef isopropanolate to loracarbef monohydrate | |
| KR19980701623A (ko) | 4,10-디아세톡시-2알파-벤조일옥시-5베타,20-에폭시-1,7베타-디히드록시-9-옥소택스-11-엔-13알파-일(2알,3에스)-3-벤조일아미노-2-히드록시-3-페닐프로피오네이트 삼수화물의 제조 방법 | |
| NO313200B1 (no) | Diclavulanatsalt med en diaminoeter, fremgangsmåte for fremstilling av et clavulansyresalt, og farmasöytisk preparatinneholdende et slikt salt | |
| EP0101170B1 (en) | Process for the manufacture of sodium cefoperazone | |
| CA2028416C (en) | Anhydrous crystal of 4-carbamoyl-1-.beta.-d-ribofuranosyl imidazolium-5-oleate | |
| GB2097791A (en) | Quaternary ammonium salt | |
| DE3519735A1 (de) | Neue heteroaromatische aminderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung | |
| HU189186B (en) | Process for producing hydrochloride of 3-cepheme-4-carboxylic acid and for purifying contaminated material by them | |
| Nudelman et al. | Rearrangements of penicillin sulfoxides. 2. Spectral data and x-ray crystallography of the novel imidazo [5, 1-c][1, 4] thiazine ring system | |
| MXPA97004641A (en) | Production of cefotaxima and new social salts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |